Clinical Trial

Biomarkers of Synaptic Damage in Multiple Sclerosis

Recruiting
View on ClinicalTrials.gov →
Summary
A prospective and retrospective cohort study of about five years will be performed on blood and cerebrospinal fluid samples taken for diagnostic reasons from recruited patients within the Neuromed Neurology Unit. Subjects with other chronic neurodegenerative diseases such as Amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD) and Parkinson's disease (PD), and healthy subjects subjected to blood sampling and / or lumbar puncture for clinical reasons will be recruited As control groups.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2017-07-12; most recent amendment 2022-10-27.
Status change: Not Yet Recruiting → Recruiting 2017-11-22
Trial Details
NCT Number NCT03217396
Lead Sponsor Neuromed IRCCS
Collaborators: IRCCS Multimedica
Conditions Multiple Sclerosis, Parkinson Disease, Amyotrophic Lateral Sclerosis, Alzheimer Disease
Enrollment 300 participants
Start Date 2017-11-22
Primary Completion 2026-09-01 (estimated)
Study Completion 2027-09-30 (estimated)
Updated on ClinicalTrials.gov 2022-10-28